Table 1 Clinicodemographic features of the non-CAD and CAD groups
|  | Non-CAD (n = 139) | Single-vessel CAD (n = 144) | Multi-vessel CAD (n = 287) | P value |
|---|---|---|---|---|
Age (year) | 51 (43, 54) | 50 (43, 54) | 52 (47, 55) | 0.002 |
Male, n (%) | 98 (70.5) | 121 (84.0) | 265 (92.3) | < 0.001 |
SBP (mmHg) | 130 (122, 148) | 129.5 (119, 144) | 134 (120, 150) | 0.220 |
DBP (mmHg) | 85 (73, 95) | 85 (75, 93) | 86 (76, 97) | 0.206 |
BMI (kg/m2) | 24.91 (22.86, 27.01) | 24.68 (22.93, 27.19) | 25.06 (23.34, 27.34) | 0.557 |
Smoking status | ||||
 Current, n (%) | 41 (29.50) | 80 (55.56) | 195 (67.94) | < 0.001 |
 Former, n (%) | 13 (9.35) | 5 (3.47) | 14 (4.88) | 0.074 |
 Never, n (%) | 85 (61.15) | 59 (40.97) | 78 (27.18) | < 0.001 |
Drinking status | ||||
 Current, n (%) | 25 (17.98) | 34 (23.61) | 58 (20.21) | 0.495 |
 Former, n (%) | 5 (3.60) | 2 (1.39) | 7 (2.44) | 0.487 |
 Never, n (%) | 109 (78.42) | 108 (75.00) | 222 (77.35) | 0.778 |
 TC (mmol/L) | 4.42 (3.89, 5.12) | 4.82 (4.08, 5.49) | 4.83 (4.18, 5.67) | 0.001 |
 TG (mmol/L) | 1.4 (1.05, 2.18) | 1.75 (1.21, 2.80) | 1.84 (1.38, 2.82) | < 0.001 |
 HDL-C (mmol/L) | 1.16 (0.90, 1.37) | 1.02 (0.88, 1.18) | 0.91 (0.80, 1.09) | < 0.001 |
 LDL-C (mmol/L) | 2.97 (2.24, 3.52) | 3.20 (2.48, 3.81) | 3.27 (2.73, 4.03) | < 0.001 |
 HbA1c (%) | 5.8 (5.6, 6.0) | 5.9 (5.6, 6.6) | 6.0 (5.7, 6.7) | < 0.001 |
 TyG index | 2.93 (2.63, 3.41) | 3.31 (2.87, 3.78) | 3.39 (3.03, 3.83) | < 0.001 |
 AIP | 0.09 (0, 0.37) | 0.24 (0.04, 0.47) | 0.31 (0.11, 0.51) | < 0.001 |
 Hypertension, n (%) | 53 (38.13) | 55 (38.19) | 136 (47.39) | 0.084 |
Glucose metabolic states | ||||
 NGR (n, %) | 93 (66.91) | 64 (44.44) | 99 (34.49) | < 0.001 |
 Pre-DM (n, %) | 31 (22.30) | 41 (28.47) | 114 (39.72) | 0.001 |
 DM (n, %) | 15 (10.79) | 38 (26.39) | 75 (26.13) | 0.001 |
Status of antihypertensive drugs | ||||
 Current, n (%) | 33 (23.74) | 34 (23.61) | 77 (26.83) | 0.687 |
 Former, n (%) | 5 (3.60) | 9 (6.25) | 28 (9.76) | 0.075 |
 Never, n (%) | 101 (72.66) | 101 (70.14) | 182 (63.41) | 0.131 |
Status of antidiabetic drugs | ||||
 Current, n (%) | 7 (5.04) | 14 (9.72) | 34 (11.85) | 0.083 |
 Former, n (%) | 0 | 1 (0.69) | 5 (1.74) | 0.228 |
 Never, n (%) | 132 (94.96) | 129 (89.58) | 248 (86.41) | 0.028 |
Status of antilipidemic drugs | ||||
 Current, n (%) | 33 (23.74) | 29 (20.14) | 51 (17.77) | 0.348 |
 Former, n (%) | 2 (1.44) | 4 (2.78) | 7 (2.44) | 0.729 |
 Never, n (%) | 104 (74.82) | 111 (77.08) | 229 (79.79) | 0.493 |
Status of antiplatelet drugs | ||||
 Current, n (%) | 26 (18.71) | 31 (21.53) | 49 (17.07) | 0.534 |
 Former, n (%) | 1 (0.72) | 2 (1.39) | 7 (2.44) | 0.416 |
 Never, n (%) | 112 (80.57) | 111 (77.08) | 231 (80.49) | 0.677 |